pharma · Myelodysplastic Syndromes (MDS) · Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)
Taiho Pharma Canada
Taiho Pharma Netherlands B.V.
Taiho Pharma Canada clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 2010 Winston Park Drive, Suite 503, Oakville, Ontario L6H 5R7, CA
- Founded
- 2017
- Employees
- 13
- Programs
- 16
- Drugs
- 30
- Patents
- 0
Taiho Pharma Canada projects
4 ClinicalTrials.gov programs sponsored by Taiho Pharma Canada.
Taiho Pharma Canada has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
ASTX030-01
Taiho Pharma Netherlands B.V.
Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)
1 trial -
Futibatinib, FULVESTRANT
Taiho Pharma Netherlands B.V.
Malignant Solid Tumors
1 trial -
TAS6417-301
Taiho Pharma Netherlands B.V.
Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
1 trial -
TAS6417-302
Taiho Pharma Netherlands B.V.
Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
1 trial
Frequently asked questions
How many clinical projects does Taiho Pharma Canada have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.